

Denka Completes Investment in Canadian Medical Device Startup Flosonics Medical

– Expanding Denka’s initiatives in digital health with a wearable and wireless ultrasound technology for blood-flow assessment –

Tokyo, Japan — Denka Co., Ltd. (Head Office: Chuo-ku, Tokyo; Representative Director, President: Ikuo Ishida) announces that it has made an investment in Flosonics Medical (Head Office: United States & Canada; CEO: Joe Eibl), a medical device startup that develops, manufactures, and commercializes a wearable ultrasound device designed to assess blood flow when applied to the skin. The investment was made through Denka’s corporate venture capital (CVC) fund, jointly operated with Pegasus Tech Ventures-



Appearance of FloPatch

Flosonics Medical is a startup company that developed FloPatch, a patch-type, wireless wearable ultrasound device. FloPatch is a device that uses an approach different from conventional blood-flow measurement to measure blood flow in real time by applying it to a patient’s neck.

In emergency medicine and intensive care settings, hemodynamic management, including assessment of circulation and blood flow, in critically ill patients, such as those with sepsis^{*1}, is a key factor that can influence patient outcomes. However, assessment of blood flow has traditionally depended on either invasive catheter-based methods that require inserting instruments into a patient’s blood vessel or conventional ultrasound systems that demand advanced operator expertise.

FloPatch provides a new option to address these challenges as a wearable ultrasound device that can visualize changes in blood flow in real-time when applied to the neck. Because it enables non-invasive and rapid assessment of hemodynamic status, FloPatch can be utilized not only by physicians but also by other healthcare professionals, such as nurses, and is expected to promote standardized care and faster clinical decision-making.

In addition, FloPatch has been cleared by the U.S. FDA under 510(k), licensed by Health Canada, and CE marked in Europe, and has been implemented at major hospitals in the United States^{*2}, particularly in emergency departments and intensive care units, where the technology is used to assist clinicians in caring for critically ill patients, including those with sepsis.

Building on the knowledge and experience Denka has cultivated through its in vitro diagnostics (IVD) business in infectious disease diagnostics, Denka aims to create new diagnostic and disease-management solutions in healthcare by leveraging digital technologies. As part of these initiatives, Denka has advanced its efforts in digital health — for example, by investing in Aevice Health Pte Ltd., a Singapore-based company developing a wearable electronic stethoscope, in fiscal year 2024. This investment in Flosonics Medical is intended to further strengthen these initiatives and expand the possibilities for collaboration with new technologies and products in the growing digital health field.

This investment is part of Denka’s efforts to create new businesses under its long-term management plan, “Mission 2030”. Denka established its CVC fund in 2023 and plans to invest up to approximately USD 100 million by fiscal year 2030. Denka will continue to create new value and help address social challenges through partnerships with innovative startups.

Guided by its Purpose — “Make the world a better place as specialists in chemistry” — Denka will continue to contribute to people’s daily lives and society through world-class chemistry.

End of Press Release

*1 Sepsis: A life-threatening organ dysfunction caused by a dysregulated host response to infection.

*2 Major hospitals in the United States: Large, advanced medical institutions ranked among the top U.S. hospitals by U.S. News, such as Sutter Health and Mount Sinai.

About Flosonics Medical:

Flosonics Medical is a medical device company engaged in the research and development of innovative ultrasound technology. Founded in 2015, the company's mission is to improve patient care and the practice of medicine through technology-enabled solutions and groundbreaking clinical research.

For more information, please visit www.flosonicsmedical.com.

[Reference: Past press releases related to this matter (our official website)]

- January 17, 2023: Signing ceremony for the establishment of CVC (Corporate Venture Capital)
https://www.denka.co.jp/eng/storage/news/pdf/476/20230117_denka_cvc_en.pdf
- January 15, 2025: Denka Completes Investment in Startup Developing Wearable Electronic Stethoscope
https://www.denka.co.jp/eng/storage/news/pdf/521/20250115_denka_Aevice%20Health_en.pdf

[For Inquiries from Media]

Corporate Communications Dept. Tel: +81-3-5290-5511

[For Inquiries from Customers]

New Business Creation Dept., New Business Development Division

Tel: +81-3-5290-5522